These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
805 related items for PubMed ID: 15712083
1. A prospective, randomized trial of structured treatment interruption for patients with chronic HIV type 1 infection. Cardiello PG, Hassink E, Ananworanich J, Srasuebkul P, Samor T, Mahanontharit A, Ruxrungtham K, Hirschel B, Lange J, Phanuphak P, Cooper DA. Clin Infect Dis; 2005 Feb 15; 40(4):594-600. PubMed ID: 15712083 [Abstract] [Full Text] [Related]
12. [HIV-1 therapy in the Netherlands; virological and immunological response to antiretroviral therapy]. Jambroes M, Weverling GJ, Reiss P, Danner SA, Jurriaans S, ten Veen JH, van der Ende ME, Schutten M, Schneider MM, Schuurman R, Mulder JW, Kroes AC, Lange JM, de Wolf F, Kliniek en Virologie van het ATHENA-project. Ned Tijdschr Geneeskd; 2001 Aug 18; 145(33):1591-7. PubMed ID: 11534377 [Abstract] [Full Text] [Related]
15. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients. Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO. West Afr J Med; 2002 Aug 18; 21(2):83-6. PubMed ID: 12403023 [Abstract] [Full Text] [Related]
16. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reichman R, Erice A, Bucy RP, Kilby JM, Lederman MM, Hamilton CD, Lertora J, White BL, Tebas P, Duliege AM, Pollard RB, AIDS Clinical Trials Group 328 Study Team. Arch Intern Med; 2007 Mar 26; 167(6):597-605. PubMed ID: 17389292 [Abstract] [Full Text] [Related]
19. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment. Sanchez R, Portilla J, Gimeno A, Boix V, Llopis C, Sanchez-Paya J, Merino E, de la Sen ML, Muñoz C, Reus S, Plazas J. J Infect; 2007 Feb 26; 54(2):159-66. PubMed ID: 16690132 [Abstract] [Full Text] [Related]